Dr. Reddy's Laboratories Ltd. (RDY)

28.96
0.36 1.23
NYSE : Health Technology
Prev Close 29.32
Open 28.16
Day Low/High 28.13 / 29.22
52 Wk Low/High 28.13 / 42.97
Volume 1.06M
Avg Volume 341.80K
Exchange NYSE
Shares Outstanding 165.87M
Market Cap 4.82B
EPS 1.10
P/E Ratio 26.41
Div & Yield 0.29 (1.01%)

Latest News

Dr. Reddy's Laboratories Announces Senior Leadership Changes

Dr. Reddy's Laboratories Announces Senior Leadership Changes

Dr. Reddy's Laboratories Ltd.

Dr. Reddy's Laboratories Announces The Launch Of Levocetirizine Dihydrochloride Tablets USP, 5 Mg In The U.S. Market

Dr. Reddy's Laboratories Announces The Launch Of Levocetirizine Dihydrochloride Tablets USP, 5 Mg In The U.S. Market

Dr. Reddy's Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has launched Levocetirizine Dihydrochloride Tablets USP, 5 mg, an over-the-counter therapeutic equivalent generic version of...

Generic Drug Sector Shifting With Legal Pressure, Changes at FDA

Generic Drug Sector Shifting With Legal Pressure, Changes at FDA

A massive price-fixing lawsuit brought by 45 states against a group of generic drug producers as well as a changing of the guard at the Food and Drug Administration may lead to changes in the generic drug sector.

Dr. Reddy's Laboratories Announces The Launch Of Tetrabenazine Tablets In The U.S. Market

Dr. Reddy's Laboratories Announces The Launch Of Tetrabenazine Tablets In The U.S. Market

Dr. Reddy's Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has launched Tetrabenazine Tablets, a therapeutic equivalent generic version of Xenazine® (tetrabenazine) in the United States...

Dr. Reddy's Laboratories is Now Oversold (RDY)

Dr. Reddy's Laboratories is Now Oversold (RDY)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

RDY Crosses Below Key Moving Average Level

RDY Crosses Below Key Moving Average Level

In trading on Thursday, shares of Dr. Reddy's Laboratories Ltd.

Dr. Reddy's Q3 And 9M FY18 Financial Results

Dr. Reddy's Q3 And 9M FY18 Financial Results

Dr. Reddy's Laboratories Ltd.

Dr. Reddy's To Release Q3 FY18 Results On January 25, 2018

Dr. Reddy's To Release Q3 FY18 Results On January 25, 2018

Dr. Reddy's Laboratories (BSE: 500124, NSE: DRREDDY, NYSE: RDY) will announce results for the Third Quarter ended December 31, 2017 on Thursday, January 25, 2018 after the Board Meeting.

Dr. Reddy's Laboratories Limited To Present At The 36th Annual J.P. Morgan Healthcare Conference

Dr. Reddy's Laboratories Limited To Present At The 36th Annual J.P. Morgan Healthcare Conference

Dr. Reddy's Laboratories Ltd (BSE: 500124)(NSE: DRREDDY)(NYSE: RDY) announced that the Company will be presenting at the 36th Annual J.

Dr. Reddy's Laboratories Announces The Launch Of Melphalan Hydrochloride For Injection In The U.S. Market

Dr. Reddy's Laboratories Announces The Launch Of Melphalan Hydrochloride For Injection In The U.S. Market

Dr. Reddy's Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has launched Melphalan Hydrochloride for Injection, a therapeutic equivalent generic version of Alkeran® (melphalan...

Drug Companies Respond to States Generic Drug Lawsuit

Drug Companies Respond to States Generic Drug Lawsuit

State attorneys general led by Connecticut's George Jepsen said Tuesday that were planning to include Mylan president Rajiv Malik and Emcure Pharmaceuticals Ltd. executive Satish Mehta in an expanded complaint in the federal generic drug antitrust lawsuit.

Dr. Reddy's Q2 And H1 FY18 Financial Results

Dr. Reddy's Q2 And H1 FY18 Financial Results

Dr. Reddy's Laboratories Ltd.

DR. REDDY'S 24 HOUR DEADLINE ALERT: Approximately 24 Hours Remain; ClaimsFiler Reminds Investors Of Deadline In Class Action Lawsuit Against Dr. Reddy's Laboratories Ltd. - (RDY)

DR. REDDY'S 24 HOUR DEADLINE ALERT: Approximately 24 Hours Remain; ClaimsFiler Reminds Investors Of Deadline In Class Action Lawsuit Against Dr. Reddy's Laboratories Ltd. - (RDY)

ClaimsFiler, a FREE shareholder information service, reminds investors that they have only until October 24, 2017 to file lead plaintiff applications in a securities class action lawsuit against Dr.

Scott+Scott, Attorneys At Law, LLP Reminds Investors Of October 24th Lead Plaintiff Deadline In Securities Class Action Against Dr. Reddy's Laboratories Limited (RDY)

Scott+Scott, Attorneys At Law, LLP Reminds Investors Of October 24th Lead Plaintiff Deadline In Securities Class Action Against Dr. Reddy's Laboratories Limited (RDY)

Scott+Scott, Attorneys at Law, LLP ("Scott+Scott"), a national shareholder and consumer rights litigation firm, reminds investors that October 24 th is the deadline for lead plaintiff motions in the securities class...

DR. REDDY'S INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Dr. Reddy's Laboratories Limited To Contact The Firm

DR. REDDY'S INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Dr. Reddy's Laboratories Limited To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Dr.

Dr. Reddy's To Release Q2 FY18 Results On October 31, 2017

Dr. Reddy's To Release Q2 FY18 Results On October 31, 2017

Dr. Reddy's Laboratories (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) will announce results for the Second Quarter ended September 30, 2017 on Tuesday, October 31, 2017 after the Board Meeting.

DR. REDDY'S SHAREHOLDER ALERT: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Dr. Reddy's Laboratories Ltd. - (RDY)

DR. REDDY'S SHAREHOLDER ALERT: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Dr. Reddy's Laboratories Ltd. - (RDY)

ClaimsFiler, a FREE shareholder information service, reminds investors that they have until October 24, 2017 to file lead plaintiff applications in a securities class action lawsuit against Dr.

DR. REDDY'S INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Dr. Reddy's Laboratories Limited To Contact The Firm

DR. REDDY'S INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Dr. Reddy's Laboratories Limited To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Dr.

DEADLINE ALERT: Brower Piven Reminds Investors Of Upcoming Deadline In Class Action Lawsuit And Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Dr. Reddy's Laboratories Ltd. To Contact The Firm

DEADLINE ALERT: Brower Piven Reminds Investors Of Upcoming Deadline In Class Action Lawsuit And Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Dr. Reddy's Laboratories Ltd. To Contact The Firm

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of...

Scott+Scott, Attorneys At Law, LLP Reminds Investors Of October 24th Lead Plaintiff Deadline In Securities Class Action Against Dr. Reddy's Laboratories Limited (RDY)

Scott+Scott, Attorneys At Law, LLP Reminds Investors Of October 24th Lead Plaintiff Deadline In Securities Class Action Against Dr. Reddy's Laboratories Limited (RDY)

Scott+Scott, Attorneys at Law, LLP ("Scott+Scott"), a national shareholder and consumer rights litigation firm, reminds investors that a securities class action has been filed against Dr.

The Klein Law Firm Reminds Investors Of Commencement Of A Class Action Filed On Behalf Of Dr. Reddy's Laboratories Ltd. Shareholders And A Lead Plaintiff Deadline Of October 24, 2017

The Klein Law Firm Reminds Investors Of Commencement Of A Class Action Filed On Behalf Of Dr. Reddy's Laboratories Ltd. Shareholders And A Lead Plaintiff Deadline Of October 24, 2017

The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Dr.

TheStreet Quant Rating: C (Hold)